PACB vs PATH
Pacific Biosciences of California (PACB) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Pacific Biosciences of California (PACB) is a medical devices company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported PACB revenue for 2025-09-30 was $38.4M. Net income was -$38.0M. Revenue was down 3.3% from 2025-06-30 to 2025-09-30. PACB currently screens at market cap $387.1M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
PACB currently screens at market cap $387.1M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the PACB and PATH stock pages for the full models.
Not investment advice.